![]() |
|
|
Vol. 30, Issue 9, 970-976, September 2002
Department of Chemical Biology, Osaka City University Medical
School, Osaka, Japan
In rats, six cytochrome P450 (P450) 2D isoforms have been
genetically identified. Nonetheless, there is little evidence of catalytic properties of each CYP2D isoform. In this study, using recombinant CYP2D isoforms (rat CYP2D1, CYP2D2, CYP2D3, and CYP2D4 and
human CYP2D6) or hepatic microsomes, we investigated the catalytic specificity toward bufuralol, debrisoquine, and propranolol, which are
frequently used as CYP2D substrates. Bufuralol was oxidized to three
metabolites by rat and human hepatic microsomes. 1'-Hydroxybufuralol was the major metabolite. 1'2'-Ethenylbufuralol, one of the others, was
identified as a novel metabolite. The formation of 1'-hydroxybufuralol and 1'2'-ethenylbufuralol in hepatic microsomes was inhibited by
anti-CYP2D antibody, suggesting that these metabolites were formed by
CYP2D isoforms. All rat and human recombinant CYP2D isoforms possessed
activity for the 1'-hydroxylation of bufuralol, indicating that this
catalytic property was common to all CYP2D isoforms. However, the
1'2'-ethenylation of bufuralol was catalyzed only by rat CYP2D4 and
human CYP2D6. Debrisoquine was oxidized to two metabolites,
3-hydroxydebrisoquine, and 4-hydroxydebrisoquine, by hepatic
microsomes. Recombinant CYP2D2 and CYP2D6 had very high levels of
activity for the 4-hydroxylation of debrisoquine with low
Km values. Only CYP2D1 had a higher level of
3-hydroxylation than 4-hydroxylation activity. Propranolol
4-hydroxylation was catalyzed by CYP2D2, CYP2D4, and CYP2D6. The
7-hydroxylation of propranolol was catalyzed only by CYP2D2. In
conclusion, in rats, bufuralol 1'2'-ethenylation activity was specific
to CYP2D4 and debrisoquine 4-hydroxylation and propranolol
7-hydroxylation activities were specific to CYP2D2. These catalytic
activities are useful as a probe for rat CYP2D isoforms.
This article has been cited by other articles:
![]() |
P. Rowland, F. E. Blaney, M. G. Smyth, J. J. Jones, V. R. Leydon, A. K. Oxbrow, C. J. Lewis, M. G. Tennant, S. Modi, D. S. Eggleston, et al. Crystal Structure of Human Cytochrome P450 2D6 J. Biol. Chem., March 17, 2006; 281(11): 7614 - 7622. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sakai, K. Saito, H.-S. Kim, A. Kazusaka, M. Ishizuka, Y. Funae, and S. Fujita IMPORTANCE OF CYP2D3 IN POLYMORPHISM OF DIAZEPAM P-HYDROXYLATION IN RATS Drug Metab. Dispos., November 1, 2005; 33(11): 1657 - 1660. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Saito, N. Sakai, H.-S. Kim, M. Ishizuka, A. Kazusaka, and S. Fujita STRAIN DIFFERENCES IN DIAZEPAM METABOLISM AT ITS THREE METABOLIC SITES IN SPRAGUE-DAWLEY, BROWN NORWAY, DARK AGOUTI, AND WISTAR STRAIN RATS Drug Metab. Dispos., September 1, 2004; 32(9): 959 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Foti and M. B. Fisher IMPACT OF INCUBATION CONDITIONS ON BUFURALOL HUMAN CLEARANCE PREDICTIONS: ENZYME LABILITY AND NONSPECIFIC BINDING Drug Metab. Dispos., March 1, 2004; 32(3): 295 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Kishimoto, T. Hiroi, M. Shiraishi, M. Osada, S. Imaoka, S. Kominami, T. Igarashi, and Y. Funae Cytochrome P450 2D Catalyze Steroid 21-Hydroxylation in the Brain Endocrinology, February 1, 2004; 145(2): 699 - 705. [Abstract] [Full Text] [PDF] |
||||